EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Management and outcomes in patients with tumor thrombus: a retrospective cohort study

Sean Hui, Khalid Zeid, Roger Kou, Ranjeeta Mallick, Marc Carrier, Tzu-Fei Wang

Journal of Thrombosis and Haemostasis · 2025-01 · 23 (1) · 201-209

DOI: 10.1016/j.jtha.2024.10.002 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025-01. Verfasst von Sean Hui und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Anticoagulants, Venous Thromboembolism, Neoplasms, Thrombosis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Tumor thrombus can be associated with an increased risk of venous thromboembolism (VTE) and poor prognosis. The risks and benefits of anticoagulation remain unclear. OBJECTIVES: To evaluate the role of anticoagulation and associated outcomes in patients with tumor thrombus. METHODS: We conducted a single-center retrospective cohort study in patients with tumor thrombus from 2019 to 2022. All patients were followed for 12 months from the diagnosis of tumor thrombus or until death if death occurred earlier. The primary outcome was the percentage of patients prescribed any dose of anticoagulation for tumor thrombus (or concurrent bland thrombus/VTE). The secondary outcomes included new thrombosis, major bleeding, clinically relevant nonmajor bleeding, and mortality. We calculated the 6- and 12-month cumulative incidence of outcomes with 95% CI and compared those given anticoagulation vs not, considering death as a competing risk. RESULTS: We included 211 patients, among whom 106 (50.2%; 95% CI, 47.9%-52.6%) were given anticoagulation for tumor thrombus or concurrent VTE (present in 21.8%). The most common type of cancer was hepatocellular carcinoma (28%). Splanchnic veins were the most commonly involved (49.3%). Anticoagulation was more likely used if tumor thrombus involved the inferior vena cava and/or the heart, with concurrent VTE, or if thrombosis service was consulted. The overall 12-month incidence of new VTE was 11.4% (95% CI, 7.3%-16.5%), that of major bleeding + clinically relevant nonmajor bleeding was 36.6% (95% CI, 29.6%-43.5%), and mortality of 52.5% (95% CI, 44.8%-59.6%), with no significant differences among groups given anticoagulation or not. CONCLUSION: Patients with tumor thrombus carry high risks of VTE, bleeding, and mortality. The impact of anticoagulation remains unclear.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsVenous ThromboembolismNeoplasmsThrombosisHumansRetrospective StudiesFemaleMaleMiddle AgedAgedHemorrhageRisk FactorsTreatment OutcomeRisk AssessmentTime FactorsAdultIncidence

Stichwörter der Autor:innen

anticoagulationhemorrhagethrombustumorvenous thromboembolism

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Department of Medicine, University of Ottawa at the Ottawa Hospital, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Department of Medicine, University of Ottawa at the Ottawa Hospital, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. Electronic address: https://twitter.com/MarcCarrier1.
  • Department of Medicine, University of Ottawa at the Ottawa Hospital, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. Electronic address: tzwang@toh.ca.

Zitieren

APA

Hui, S., Zeid, K., Kou, R., Mallick, R., Carrier, M., & Wang, T. F. (2025). Management and outcomes in patients with tumor thrombus: a retrospective cohort study. Journal of Thrombosis and Haemostasis, 23(1), 201-209. https://doi.org/10.1016/j.jtha.2024.10.002

Vancouver

Hui S, Zeid K, Kou R, Mallick R, Carrier M, Wang TF. Management and outcomes in patients with tumor thrombus: a retrospective cohort study. Journal of Thrombosis and Haemostasis. 2025;23(1):201-209. doi:10.1016/j.jtha.2024.10.002

BibTeX
@article{Hui2025,
  author = {Hui, Sean and Zeid, Khalid and Kou, Roger and Mallick, Ranjeeta and Carrier, Marc and Wang, Tzu-Fei},
  title = {Management and outcomes in patients with tumor thrombus: a retrospective cohort study},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  volume = {23},
  number = {1},
  pages = {201--209},
  doi = {10.1016/j.jtha.2024.10.002}
}
Kostenlos starten →